NT-125

NT-125 is an autologous, fully individualized, multi-specific T cell receptor (TCR) T cell therapy targeting patient-specific neoantigens in advanced solid tumors. It is manufactured from a patient’s own T cells, which are engineered—using a non-viral gene transfer platform such as the Sleeping Beauty transposon/transposase system—to express up to five distinct neoantigen-specific TCRs per product, with the goal of reducing antigen escape and achieving deep, durable responses in difficult-to-treat solid cancers including lung, colorectal, and head and neck tumors.[2][3][6][9][10] Functionally, NT-125 acts as a gene therapy and T lymphocyte cell therapy that mediates immunologic cytotoxicity and T lymphocyte replacement by redirecting the patient’s T cells to recognize and kill tumor cells presenting the targeted neoantigen-derived peptides on HLA molecules.[1][3][10] The program was originally developed by Neogene Therapeutics and subsequently advanced by AstraZeneca after its acquisition of Neogene, but the Phase 1 solid tumor program was discontinued for strategic reasons following early clinical development.[2][3][5][7][10]

Other names

personalized neoantigen-specific T-cell receptor T cellsNeo-TCR-T